Replies to post #215102 on Biotech Values

[Titan V]

Moderna Announces First-in-Human Dosing for Phase 1 Study (KEYNOTE-603) of mRNA-4157, a Personalized Cancer Vaccine, for the Treatment of Solid Tumors
http://www.businesswire.com/news/home/20171115005760/en/Moderna-Announces-First-in-Human-Dosing-Phase-1-Study

--Novel cancer vaccine encodes 20 neoepitopes on a single mRNA molecule to elicit a completely individualized immune response--

--Moderna and Merck collaborating to evaluate mRNA-4157 in combination with KEYTRUDA® (pembrolizumab)

———

This $5 Billion Startup Made Its First Cancer Vaccine—For Just One Person
https://www.bloomberg.com/news/features/2017-11-15/this-5-billion-startup-made-its-first-cancer-vaccine-for-just-one-person